4//SEC Filing
LEUTZINGER KURT 4
Accession 0001209191-12-003887
CIK 0001301081other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:04 PM ET
Size
28.3 KB
Accession
0001209191-12-003887
Insider Transaction Report
Form 4
Pharmasset IncVRUS
LEUTZINGER KURT
Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−125,000→ 0 totalExercise: $1.50Exp: 2015-01-17→ Common Stock (125,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−62,000→ 0 totalExercise: $6.84Exp: 2017-10-10→ Common Stock (62,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−51,000→ 0 totalExercise: $2.01Exp: 2016-11-07→ Common Stock (51,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−68,500→ 0 totalExercise: $1.94Exp: 2016-05-24→ Common Stock (68,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−20,000→ 0 totalExercise: $9.30Exp: 2018-10-29→ Common Stock (20,000 underlying) - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−75,300$10,316,100→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−75,000→ 0 totalExercise: $83.52Exp: 2021-10-11→ Common Stock (75,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−59,000→ 0 totalExercise: $16.17Exp: 2020-10-14→ Common Stock (59,000 underlying) - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−222,232$30,445,784→ 0 total - Disposition from Tender
Common Stock
2012-01-12$137.00/sh−75,300$10,316,100→ 0 total(indirect: By Trust) - Disposition to Issuer
Stock Option (Right to Buy)
2012-01-12−50,000→ 0 totalExercise: $10.83Exp: 2019-10-14→ Common Stock (50,000 underlying)
Footnotes (10)
- [F1]Represents shares owned by the Kurt Leutzinger 2011 Irrevocable Trust for the benefit of Jessica Falencki, of which Yvonne Leutzinger, Mr. Leutzinger's spouse, is the sole trustee. Mr. Leutzinger disclaims beneficial ownership of such shares except to the extent of his direct pecuniary interest therein, and this filing shall not be deemed an admission that Mr. Leutzinger is, for the purposes of Section 16 or for any other purpose, the beneficial owner of such shares.
- [F10]These options, which provided for vesting as to 25% on the first anniversary of the date of grant (October 11, 2011) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $53.48 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F2]Represents shares owned by the Kurt Leutzinger 2011 Irrevocable Trust for the benefit of Michelle Leutzinger, of which Yvonne Leutzinger, Mr. Leutzinger's spouse, is the sole trustee. Mr. Leutzinger disclaims beneficial ownership of such shares except to the extent of his direct pecuniary interest therein, and this filing shall not be deemed an admission that Mr. Leutzinger is, for the purposes of Section 16 or for any other purpose, the beneficial owner of such shares.
- [F3]These options, which reflect the two-for-one stock split of the Issuer's common stock effective August 31, 2011 (the "Split") and which vested as to 25% on the first anniversary of the date of grant (January 17, 2005) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Gilead Sciences, Inc. (the "Merger Agreement") in exchange for a cash payment of $135.50 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F4]These options, which reflect the Split and which vested as to 25% on January 17, 2007 and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $135.06 per share, representing the difference between the exercise price of the options and $137.00 per share. These options were granted on May 24, 2006.
- [F5]These options, which reflect the Split and which vested as to 25% on the first anniversary of the date of grant (November 7, 2006) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $134.99 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F6]These options, which reflect the Split and which vested as to 25% on the first anniversary of the date of grant (October 10, 2007) and as to an additional 6.25% quarterly thereafter for the following three years, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $130.16 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F7]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 29, 2008) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $127.70 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F8]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 14, 2009) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $126.17 per share, representing the difference between the exercise price of the options and $137.00 per share.
- [F9]These options, which reflect the Split and which provided for vesting as to 25% on the first anniversary of the date of grant (October 14, 2010) and as to an additional 6.25% quarterly thereafter for the following three years, became fully vested and were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $120.83 per share, representing the difference between the exercise price of the options and $137.00 per share.
Documents
Issuer
Pharmasset Inc
CIK 0001301081
Entity typeother
Related Parties
1- filerCIK 0001211704
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:04 PM ET
- Size
- 28.3 KB